<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[shire Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/shire.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to shire]]></description>
	<s:counts start="0" returned="20" found="24" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Shire Contemplates Off-Label Use of Intuniv, Vyvanse]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004095/shire-contemplates-off-label-use-of-intuniv-vyvanse/]]></link>
		<description><![CDATA[The FDA's approval of Intuniv brings to four the number of drugs for ADHD currently marketed by Shire. Management is already contemplating whether the drugs will be used off-label. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 04 Sep 2009 08:42:26 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[UPDATED: Shire Accused of Depriving Family of Metazym Even Though They Raised â‚¬1M to Buy It]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003103/shire-accused-of-depriving-family-of-metazym-even-though-they-raised-e1m-to-buy-it/]]></link>
		<description><![CDATA[A British family has accused a Denmark drug company of reneging on a promise to sell them a supply of Metazym for their fatally ill daughter and instead giving it to Shire. Shire has declined to supply the family with the experimental drug, saying it does not have enough of...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 14 Jul 2009 09:36:19 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/family.html"><![CDATA[Family]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Shire CEO Says His ADHD Market Share Dropped 10 Percentage Points]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002560/shire-ceo-says-his-adhd-market-share-dropped-10-percentage-points/]]></link>
		<description><![CDATA[Shire's grip over the ADHD market with Adderall XR and its replacement drug, Vyvanse, appears to be weakening due to generic competition, according to CEO Angus Russell. In an interview with Reuters Russell said Shire's share had slipped from 26 percent to 16 percent. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 05 Jun 2009 13:12:48 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Shire CEO Compensation Report Successfully Conceals CEO Compensation]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001461/shire-ceo-compensation-report-successfully-conceals-ceo-compensation/]]></link>
		<description><![CDATA[Shire, the British company that markets Adderall and Vyvanse, has produced a compensation report for its senior executives that is all but impossible to understand.    The disclosure, starting on page 52 of the annual report, describes the compensation of just three of its top executives -- former...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 25 Mar 2009 08:05:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/compensation.html"><![CDATA[Compensation]]></category>
		<category domain="http://resources.bnet.com/topic/exec.html"><![CDATA[Exec]]></category>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/values.html"><![CDATA[Values]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[The Pfizer-Shire Deal Worst-Case Scenario]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000569/the-pfizer-shire-deal-worst-case-scenario/]]></link>
		<description><![CDATA[Earlier this week shares of Shire rose on rumors that Pfizer may be interested in acquiring the company, which is best-known for its ADHD drug Adderall XR. The notion that Pfizer is in acquisition mode has been driving people crazy for days. (See BNET's coverage of Pfizer Pfever here.) ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 07 Jan 2009 14:00:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/medicaid.html"><![CDATA[Medicaid]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/adhd.html"><![CDATA[ADHD]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[Vyvanse]]></category>
		<category domain="http://resources.bnet.com/topic/barr.html"><![CDATA[Barr]]></category>
		<category domain="http://resources.bnet.com/topic/cola.html"><![CDATA[Cola]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Shire's Big Gamble on ADHD Drug Vyvanse]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000202/shires-big-gamble-on-adhd-drug-vyvanse/]]></link>
		<description><![CDATA[One of the recent unheralded successes of the drug world was Shire Pharmaceuticals' launch of Vyvanse, a new, long-acting treatment for attention deficit and hyperactivity disorder. The fact that so little attention has been paid to Vyvanse is a shame because the take-up of this drug has been impressive --...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 04 Sep 2008 09:03:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[Vyvanse]]></category>
		<category domain="http://resources.bnet.com/topic/sanofi.html"><![CDATA[Sanofi]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Shire in a spin over Vyvanse.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5986/is_200802/ai_n25291356]]></link>
		<description><![CDATA[Shires shares have plummeted after high-profile brokers downgrade  them on concerns customers aren't switching to its  new ADHD drug,  Vyvanse Richard Hemming     First it was US-based broker Sanford C. Bernstein, then it was  Goldman Sachs. Shire's share price has fallen off a...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 06 Feb 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/goldman+sachs+group+inc..html"><![CDATA[Goldman Sachs Group Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GS</category>
		<category domain="tickers">GS</category>
	</item>
	<item>
		<title><![CDATA[Shire Successfully Completes Tender Offer for New River Shares.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200704/ai_n23616337]]></link>
		<description><![CDATA[BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, April 18  /PRNewswire/ --     Shire plc (LSE: SHP.L; NASDAQ: SHPGY; TSX: SHQ)  ("Shire" or the "Company") announced today that its  wholly owned subsidiary, Shuttle Corporation ("Shuttle"),  successfully completed its tender offer for the outstanding shares of ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 18 Apr 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/merger.html"><![CDATA[merger]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Results of Extraordinary General Meeting Held on 16 April 2007.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200704/ai_n23612705]]></link>
		<description><![CDATA[BASINGSTOKE, England, April 16 /PRNewswire/ --     Shire plc (LSE:  SHP.L; NASDAQ: SHPGY; TSX: SHQ) ("Shire" or the  "Company") announced today that its shareholders approved the  proposed acquisition of New River Pharmaceuticals Inc. (NASDAQ: NRPH)  ("New River") at the Shire Extraordinary General Meeting...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 16 Apr 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/shareholder.html"><![CDATA[shareholder]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Shire's Elaprase gets Greek distributor]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5781/is_200704/ai_n23787186]]></link>
		<description><![CDATA[DISTRIBUTIONShire UK has chosen Samaritan Pharmaceutical US to market Elaprase, its treatment for Hunter syndrome, in Greece and Cyprus.Elaprase idursulfase was granted marketing authorization for the longterm treatment of patients with Hunter syndrome by the European Commission in January, having been given the green light in the US in July...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sun, 01 Apr 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/european+commission.html"><![CDATA[European Commission]]></category>
		<category domain="http://resources.bnet.com/topic/greece.html"><![CDATA[Greece]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/syndrome.html"><![CDATA[syndrome]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Shire Announces Posting of Circular, Date of Extraordinary General Meeting and Extension of Tender Offer for New River Shares Until April 17, 2007.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200703/ai_n23607993]]></link>
		<description><![CDATA[BASINGSTOKE, England, March 26 /PRNewswire/ --     Shire plc (LSE:  SHP.L; NASDAQ: SHPGY; TSX: SHQ) ("Shire" or the  "Company") today announced the date of an Extraordinary  General Meeting ("EGM") of its shareholders to approve the  proposed acquisition of New River Pharmaceuticals Inc. (NASDAQ:...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 26 Mar 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/shareholder.html"><![CDATA[shareholder]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[SHIRE PLC - Merger Update.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200703/ai_n23963533]]></link>
		<description><![CDATA[SHIRE ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD    Basingstoke, UK - March 19, 2007 - Shire plc (LSE: SHP.L; NASDAQ: SHPGY; TSX:  SHQ) today announced that the waiting period under the Hart-Scott-Rodino  Antitrust Improvements Act of 1976 HSR with respect to its wholly owned  subsidiary's...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 19 Mar 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/merger.html"><![CDATA[merger]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[SHIRE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Shire plc to Acquire New River Pharmaceuticals.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200702/ai_n19692838]]></link>
		<description><![CDATA[M2 PRESSWIRE-20 February 2007-Early Watch: Shire plc to Acquire New  River PharmaceuticalsC1994-2007 M2 COMMUNICATIONS LTD    RDATE:20022007    New River Pharmaceuticals Inc. (NASDAQ:NRPH) is a specialty  pharmaceutical company developing novel pharmaceuticals that are  generational improvements of widely prescribed drugs in large and ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 20 Feb 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[security]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Shire Announces US$800 Million Equity Financing in Connection With Acquisition of New River.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200702/ai_n23602680]]></link>
		<description><![CDATA[BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, February 20  /PRNewswire/ --     Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ)  ("Shire") announces today that, to part-finance its proposed  acquisition by way of tender offer and merger of New River  Pharmaceuticals Inc, it plans to raise...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 20 Feb 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/england.html"><![CDATA[England]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[security]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[SHIRE PLC - Equity financing.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200702/ai_n23963204]]></link>
		<description><![CDATA[SHIRE ANNOUNCES $800 MILLION EQUITY FINANCING                    IN CONNECTION WITH ACQUISITION OF NEW RIVER    Basingstoke, UK and Philadelphia, US - February 20, 2007 - Shire plc (LSE: SHP, ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 20 Feb 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/acquisition.html"><![CDATA[acquisition]]></category>
		<category domain="http://resources.bnet.com/topic/equity.html"><![CDATA[equity]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/financing.html"><![CDATA[financing]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[investor]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[security]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[SHIRE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200612/ai_n23588404]]></link>
		<description><![CDATA[BASINGSTOKE, England, PHILADELPHIA and RADFORD, Virginia, December  22 /PRNewswire/ --    - Launch Expected Q2 2007    New River Pharmaceuticals Inc. (Nasdaq: NRPH) and its collaborative  partner Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced today  that the U.S. Food and Drug...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 22 Dec 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/readers.html"><![CDATA[Readers]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[VYVANSE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Issues Updates of Shire plc.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200610/ai_n20258221]]></link>
		<description><![CDATA[M2 PRESSWIRE-20 October 2006-www.MarketGainer.com: Issues Updates  of Shire plcC1994-2006 M2 COMMUNICATIONS LTD    RDATE:20102006    Market Gainer is quickly emerging as the one stop shop for  international small-cap investors looking to stay a step ahead of the  markets. Today's activity on the Nasdaq...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 20 Oct 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/hunter.html"><![CDATA[Hunter]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/syndrome.html"><![CDATA[syndrome]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[ADDERALL XR(R) - Paragraph IV Notice Received.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200610/ai_n23562755]]></link>
		<description><![CDATA[BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, October 3  /PRNewswire/ --     Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) -  Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that it has  received a Paragraph IV notice letter from Andrx Pharmaceuticals, L.L.C.  Andrx advising...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 03 Oct 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Shire's attention deficit disorder blow.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6602/is_200606/ai_n26021018]]></link>
		<description><![CDATA[The controversy over the safety of attention deficit hyperactivity  disorder ADHD medicines, including Shire's Adderall XR, was  renewed this week following the results of a study published in the New  England Journal of Medicine.    Using US government figures, the report estimates that 3,000 ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 02 Jun 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+government.html"><![CDATA[U.S. Government]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Attention deficit boost for Shire.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6602/is_200505/ai_n26018014]]></link>
		<description><![CDATA[Shire unveiled positive data from Phase III trials of its new  attention-deficit disorder drug NRP104 at a conference this week. And  analysts at Morgan Stanley claim that the drug could be a blockbuster.  But Japanese bank Nomura cut its recommendation on Shire from buy to  reduce,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 27 May 2005 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/analyst.html"><![CDATA[analyst]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/blockbuster.html"><![CDATA[blockbuster]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/morgan+stanley.html"><![CDATA[Morgan Stanley]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MS</category>
		<category domain="tickers">MS</category>
	</item>
</channel>
</rss>
